Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,474 across all filing types
Latest filing 2019-05-16 Proxy Solicitation & In…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Proposal for Adoption of Share Option Scheme and Notice of Extraordinary General Meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a circular from Ascletis Pharma Inc. regarding the proposal for adoption of a Share Option Scheme and notice of an Extraordinary General Meeting (EGM). It includes detailed information about the scheme, definitions, a letter from the board, and a notice of the EGM where the proposal will be considered. The document is not a financial report, earnings release, or regulatory filing but rather a solicitation and information document sent to shareholders to inform them about the proposal and request their vote at the EGM. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings such as EGMs.
2019-05-16 English
Notification Letter to Non-Registered Holders of Shares with Request Form - Notice of Publication of Circular containing Notice of Annual General Meeting
Report Publication Announcement Classification · 95% confidence The document is a letter dated 7 May 2019 from Ascletis Pharma Inc. addressed to non-registered shareholders. It informs recipients that the company's Circular containing the Notice of Annual General Meeting (AGM) is available on the company's and HKExnews websites. It also includes a request form for shareholders to receive printed versions of corporate communications, including the Circular. The document does not contain the Circular itself or any AGM materials but is an announcement about the availability of the Circular and instructions on how to request a printed copy. The document length is 6254 characters, which is relatively short and consistent with an announcement rather than a full report. According to the "Menu vs Meal" rule, this is a Report Publication Announcement (RPA) because it announces the availability of the Circular (which is AGM-related material) but does not include the AGM materials themselves.
2019-05-06 English
Form of Proxy for the 2019 Annual General Meeting
AGM Information Classification · 100% confidence The document is a 'Form of Proxy' for the 2019 Annual General Meeting (AGM) of Ascletis Pharma Inc. It includes instructions for shareholders to appoint proxies to vote on resolutions at the AGM, including receiving and considering the audited financial statements and reports for the year ended 31 December 2018, re-election of directors, appointment of auditors, and granting mandates related to share issuance and repurchase. This document is not the actual AGM presentation or materials but a proxy form related to the AGM. According to the filing definitions, materials shared during the AGM, including proxy forms, fall under 'AGM Information (AGM-R)'. The document length and content confirm it is not a brief announcement or a report publication notice but a substantive proxy form for the AGM.
2019-05-06 English
Notice of 2019 Annual General Meeting
AGM Information Classification · 100% confidence The document is a notice of the 2019 Annual General Meeting (AGM) for Ascletis Pharma Inc. It includes details about the meeting date, location, agenda items such as receiving and considering audited financial statements, re-election of directors, appointment of auditors, and approval of share issuance and repurchase mandates. The document is clearly a meeting notice rather than the actual annual report or financial statements. It is a formal announcement to shareholders about the AGM and the business to be transacted there. Therefore, it fits the category of AGM Information (AGM-R). The document length (10,101 characters) is consistent with a detailed AGM notice, not a brief announcement or a full report.
2019-05-06 English
Proposals for General Mandates to Issue Shares and to Repurchase Shares, Re-election of Directors and Notice of Annual General Meeting
AGM Information Classification · 95% confidence The document is a circular to shareholders of Ascletis Pharma Inc. regarding proposals for general mandates to issue and repurchase shares, re-election of directors, and notice of the Annual General Meeting (AGM). It includes detailed information about the meeting agenda, explanatory statements, and proxy forms. The content is typical of materials sent to shareholders ahead of an AGM to inform them about resolutions to be voted on. It is not the AGM minutes or presentation itself, but the circular containing proposals and notices related to the AGM. Therefore, this document fits the category of AGM Information (AGM-R). The document length is substantial (15,000 characters), indicating it is not a brief announcement but a full circular. Hence, the classification is AGM Information (AGM-R) with high confidence.
2019-05-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2019
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions for the month ended 30/4/2019. The content focuses on share capital changes and confirmations related to securities issuance. There is no indication of financial performance data, management discussion, earnings, or audit information. The document is a regulatory filing reporting share capital movements and related confirmations to the stock exchange, consistent with a regulatory compliance disclosure rather than a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS).
2019-05-06 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.